Related Experiment Video
Updated: May 9, 2026
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
[Small interfering RNA-mediated RIP1 knockdown enhances L-OHP sensitivity of human oral squamous carcinoma cells]
Jincheng Xu1, Yingying Huang, Yang Li
1Department of Stomatology, First Affiliated Hospital of Bengbu Medical College, Bengbu, China. xjch9999@163.com
Objective:
To investigate the effect of small interfering RNA-mediated receptor-interacting protein kinase 1 (RIP1) knockdown on the sensitivity of human oral squamous carcinoma cells to to oxaliplatin (L-OHP)-induced apoptosis and explore a new target for clinical treatment of oral squamous carcinoma.
Methods:
The viability of human oral squamous carcinoma cell line KB exposed to different concentrations (0, 0.25, 0.5, 1, 2, 4 µmol/L) of L-OHP were detected by MTT assay. PI/Annexin V staining was used to observe cell apoptosis in naive KB cells, cell and transfected with pSH1Si-RIP1 or with the empty plasmid. Western blotting was used to detect RIP1 expression in KB cells exposed to L-OHP and in cells transfected with pSH1Si-RIP1.
Results:
Exposure to L-OHP (1µmol/L) for 24, 48, 72 h resulted in KB cell survival rates of 67.66%, 55.17%, and 41.34%, respectively, but the cell apoptosis rate was only 9.6% following a 24-h exposure. KB cells transfected with pSH1Si-RIP1 showed an apoptotic rate of 9.4%, which increased to 29.1% following L-OHP exposure. RIP1 expression was first up-regulated and then down-regulated in KB cells treated with L-OHP, and was significantly reduced after cell transfection with pSH1Si-RIP1.
Conclusion:
Suppression of RIP1 expression increases the apoptotic rate of human oral squamous carcinoma cells, suggesting the potential of RIP1 as a new candidate target for clinical treatment of oral squamous carcinoma.
Insights
Knocking down receptor-interacting protein kinase 1 (RIP1) in oral cancer cells significantly increases their sensitivity to oxaliplatin-induced apoptosis. This suggests RIP1 is a promising therapeutic target for oral squamous carcinoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Oral squamous carcinoma (OSCC) is a prevalent malignancy with limited treatment options.
- Oxaliplatin (L-OHP) is a platinum-based chemotherapy agent used in cancer treatment.
- Receptor-interacting protein kinase 1 (RIP1) is implicated in cell death pathways.
Purpose of the Study:
- To evaluate the impact of small interfering RNA (siRNA)-mediated RIP1 knockdown on L-OHP-induced apoptosis in human OSCC cells.
- To explore RIP1 as a potential therapeutic target for OSCC.
Main Methods:
- Human OSCC cell line KB was treated with varying concentrations of L-OHP.
- Cell viability was assessed using the MTT assay.
- Apoptosis was measured by PI/Annexin V staining.
- RIP1 expression was analyzed via Western blotting after L-OHP treatment and RIP1 knockdown using pSH1Si-RIP1.
Main Results:
- L-OHP treatment alone resulted in limited apoptosis (9.6%) in KB cells.
- siRNA-mediated RIP1 knockdown in KB cells increased the apoptotic rate to 29.1% upon L-OHP exposure.
- RIP1 expression initially increased then decreased with L-OHP treatment, and was significantly reduced by pSH1Si-RIP1 transfection.
Conclusions:
- Suppression of RIP1 expression enhances the apoptotic response of human OSCC cells to oxaliplatin.
- RIP1 represents a potential novel therapeutic target for the clinical management of oral squamous carcinoma.
Related Concept Videos
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...